Teva's Lucky Number Seven: Analysis Supports Shorter Exclusivity For Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
Paper by AEI fellow Brill challenges the assumptions in the 16-year estimate from Duke's Grabowski.
You may also be interested in...
Exclusivity For Biologics, Drugs Should Be The Same After All, Grabowski Says
Duke University economics professor Henry Grabowski and his colleagues suggest the Hatch-Waxman statute be revised to mirror biosimilars legislation and provide 12 years of market exclusivity.
Will Waxman Offer Seven Years Of Exclusivity For Follow-On Biologics?
Revised bill is expected shortly as Reps. Eshoo and Barton draw battle line against the Commerce Committee chairman.